Teva Pharmaceutical Industries (MEX:TEVA N) Moat Score : 6/10 (As of Jul. 16, 2025)

View and export this data going back to 2011. Start your Free Trial

What is Teva Pharmaceutical Industries Moat Score?

Teva Pharmaceutical Industries has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Teva Pharmaceutical Industries has Narrow Moat: Teva has a strong position in the generic pharmaceuticals market with significant economies of scale and a broad distribution network. It holds valuable patents and benefits from regulatory barriers. However, it faces intense competition and lacks strong brand loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Teva Pharmaceutical Industries might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Competitive Comparison of Teva Pharmaceutical Industries's Moat Score

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries's Moat Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Moat Score distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Moat Score falls into.

Save Embed

;

Save Embed

;

Teva Pharmaceutical Industries (MEX:TEVA N) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

Teva Pharmaceutical Industries Moat Score Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (MEX:TEVA N) » Definitions » Moat Score

Traded in Other Exchanges

TEVJF:USA TEVA:USA TEVA:Israel 0LER:UK TEV:Germany TEV:Germany T1EV34:Brazil TEV:Bulgaria TEVA:Austria

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Teva Pharmaceutical Industries Headlines

No Headlines